Brokerages Expect Ocera Therapeutics, Inc. (OCRX) Will Post Earnings of -$0.20 Per Share
Equities analysts forecast that Ocera Therapeutics, Inc. (NASDAQ:OCRX) will post earnings of ($0.20) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Ocera Therapeutics’ earnings. Ocera Therapeutics posted earnings of ($0.22) per share in the same quarter last year, which indicates a positive year over year growth rate of 9.1%. The business is expected to report its next earnings report on Friday, March 9th.
According to Zacks, analysts expect that Ocera Therapeutics will report full year earnings of ($0.93) per share for the current financial year. For the next year, analysts expect that the business will post earnings of ($0.95) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Ocera Therapeutics.
Ocera Therapeutics (NASDAQ:OCRX) last released its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.24).
An institutional investor recently raised its position in Ocera Therapeutics stock. Hikari Power Ltd boosted its holdings in shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) by 79.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 676,596 shares of the biopharmaceutical company’s stock after buying an additional 300,000 shares during the quarter. Hikari Power Ltd owned 2.55% of Ocera Therapeutics worth $771,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 17.69% of the company’s stock.
Shares of Ocera Therapeutics (OCRX) opened at $1.77 on Wednesday. Ocera Therapeutics has a 1-year low of $0.52 and a 1-year high of $2.95.
Ocera Therapeutics Company Profile
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.